Ritonavir

Although RTV was initially developed as a PI for HIV treatment, RTV is currently used at a lower dose of 100 mg to 200 mg once or twice daily as a PK enhancer to increase the concentrations of other PIs.

ARV U.S. Brand Name

Norvir

ARV Abbreviation(s)

RTV

U.S. FDA Label

Ritonavir Labeling (Package Insert)

ARV Class

Pharmacokinetic enhancers

First U.S. Approval

January 15, 2015

U.S. Manufacturer

Abbvie

Formulations

Strength	Formulation	Image	Description	Boosted
100 mg	Film-Coated Tablets	X	oval white tablet with design and "NK" imprint	No
80-mg/mL	Oral Solution	X	bottle with norvir ritonavir oral solution 80 mg per mL on label	No
100-mg/packet	Oral Suspension Powder	X	Ritonavir oral powder in individual packets sitting on top of box	No

Generic Available?

Yes

Other Reference Links

Clinical Info HIV Drug Database

National HIV Curriculum

Assistance Programs

myAbbVie Assist

Displaying 1 - 85 of 85

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Rilpivirine (IM) Darunavir/ritonavir	Green: Administer standard doses	Administer standard doses
Lenacapavir Atazanavir/ritonavir	Red: Avoid combination	Do not coadminister: potentially increased levels of lenacapavir	Potential increase in lenacapavir adverse effects				Use alternative agents
Ritonavir Midazolam 1104	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Not studied (may increase midazolam levels)	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.
Ritonavir Theophylline 1103	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased theophylline effects		3 mg / kg Q8H	Theophylline AUC decreased 43%; Cmax decreased 32%; Cmin decreased 57%; half-life: decreased 57%	Monitor and adjust theophylline as clinically indicated
Ritonavir Itraconazole 1102	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased ritonavir effects	Increased ritonavir levels)			If coadministering, consider keeping doses of itraconazole < 200 mg daily
Ritonavir Flecainide 1101	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased flecainide effects (eg, cardiac arrhythmias)	Not studied		Not studied (may increase flecainide levels)	If coadministering use with caution and monitor for toxicity. Consider therapeutic drug monitoring
Ritonavir Meperidine 1100	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased normeperidine effects		50 mg PO x 1 dose	Meperidine AUC decreased 67%; normeperidine AUC increased 47%	If coadministering monitor for pain control and adjust dose as indicated
Ritonavir Ketoconazole 1099	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased ritonavir effects	Increased ritonavir levels)			If coadministering consider keeping doses of ketoconazole < 200 mg daily
Ritonavir Tacrolimus 1098	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased tacrolimus effects (eg, bone marrow suppression)		4 mg BID		If coadministering consider initiating lower immunosuppressant dose to account for potential increased concentrations and monitor for toxicities. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
Ritonavir Alprazolam 1097	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination			1 mg x 1	Alprazolam AUC no significant change; Cmax decreased 16%	Avoid combination and use alternative agents
Ritonavir Alprazolam 1096	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased alprazolam effects (eg, increased sedation, confusion, respiratory depression)		1 mg x 1 dose	Alprazolam clearance: decreased 59%; half-life: increased 122%	Avoid combination and use alternative agents
Ritonavir Diazepam 1095	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased diazepam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Increased diazepam levels	Use alternative agents
Ritonavir Apixaban 1094	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding	Not studied		Not studied (may increase levels) of apixaban.	Avoid combination; use alternative anticoagulant
Ritonavir Ticagrelor 1093	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding	Not studied		Not studied (may increase ticagrelor levels)	Avoid combination and use alternative antiplatelet agent
Ritonavir Vorapaxar 1092	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding	Not studied		Not studied (may increase effects of vorapaxar	Avoid combination and use alternative antiplatelet agent
Ritonavir Rivaroxaban 1091	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding	Not studied		Not studied (may increase rivaroxaban levels)	Avoid combination and use alternative anticoagulant
Ritonavir Phenytoin 1090	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased phenytoin effects	Not studied		Increased phenytoin levels)	Avoid combination and use alternative agents. Monitor phenytoin levels and adjust as indicated. Monitor virologic response.
Ritonavir Quinine 1089	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased quinine effects	Ritonavir AUC increased 21%; Cmax increased 15%	600 mg x 1	Quinine AUC increased 341%; Cmax increased 284%	Avoid combination and use alternative agents. If combination must be used a potential four-fold reduction in quinine dosage may be needed
Ritonavir CBZ 1088	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased carbamazepine effects; decreased ritonavir effects	Decreased ritonavir levels)	350 mg BID	Not studied (may increase carbamazepine levels)	Avoid combination and use alternative agents. If coadministering monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Ritonavir Voriconazole 1087	Red: Avoid combination	Do not coadminister: Reduced levels of voriconazole	Decreased voriconazole effects	No significant change	400 mg Q12H	Voriconazole AUC decreased 83%; Cmax decreased 68%	Do not coadminister with ritonavir or other ritonavir-boosted protease inhibitors unless benefit outweighs risks. If coadministering consider therapeutic drug monitoring.
Ritonavir Voriconazole 1086	Red: Avoid combination	Do not coadminister: Reduced levels of voriconazole	Decreased voriconazole effects	No significant change	400 mg Q12H	Voriconazole AUC decreased 39%; Cmax decreased 24%	Do not coadminister with ritonavir or other ritonavir-boosted protease inhibitors unless benefit outweighs risks. If coadministering consider therapeutic drug monitoring.
Ritonavir RIF 1085	Red: Avoid combination	Do not coadminister: Reduced levels of ritonavir	Decreased ritonavir effects	Ritonavir AUC decreased 35%; Cmax decreased 25%	300 mg or 600 mg x 10 days		Use alternative agents
Ritonavir Ethinyl estradiol / Norethindrone acetate 1084	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol	Decreased oral contraceptive effectiveness		50 mcg x 2 doses	Ethinyl estradiol Cmax decreased 32%; AUC decreased 41%	Use alternative contraceptive method
Ritonavir St. John's Wort (Hypericum perforatum) 1083	Red: Avoid combination	Do not coadminister: Potential for reduced levels of ritonavir	Decreased ritonavir effects	Not studied (may decrease ritonavir levels)		Not studied	Contraindicated. Use alternative agents.
Ritonavir Quinidine 1082	Red: Avoid combination	Do not coadminister: Potential for increased levels of quinidine	Increased quinidine effects (eg, cardiac arrhythmias)	Not studied		Not studied (may increase quinidine levels)	Use alternative agents
Ritonavir Propafenone 1081	Red: Avoid combination	Do not coadminister: Potential for increased levels of propafenone	Increased propafenone effects (eg, cardiac arrhythmias)	Not studied		Not studied (may increase propafenone levels)	Use alternative agents
Ritonavir Pimozide 1080	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Increased pimozide effects (eg, hypotension, cardiac arrhythmias)	Not studied		Not studied (may increase pimozide levels)	Contraindicated. Use alternative agents.
Ritonavir Ergotamine 1079	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Increased ergotamine effects (eg, ergotism)	Not studied		Not studied (may increase ergotamine levels)	Contraindicated. Use alternative agents.
Ritonavir ATV/c 1078	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Not studied		Not studied; Potential increased atazanavir levels)	Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
Ritonavir Amiodarone 1077	Red: Avoid combination	Do not coadminister: Potential for increased levels of amiodarone	Increased amiodarone effects (eg, cardiac arrhythmias)	Not studied		Not studied (may increase amiodarone levels)	Do not coadminister
Ritonavir Alfuzosin 1076	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin		Not studied		Not studied (may increase alfuzosin levels)	Use alternative agents
Ritonavir Tinidazole 1075	Red: Avoid combination	Do not coadminister: potential toxicity	Disulfiram-like reaction (eg, headache, hypotension, flushing, vomiting)	Not studied		Not studied	Do not coadminister with ritonavir solution
Ritonavir Metronidazole 1074	Red: Avoid combination	Do not coadminister: potential toxicity	Disulfiram-like reaction (eg, headache, hypotension, flushing, vomiting)	Not studied		Not studied	Do not coadminister with ritonavir solution
Ritonavir Disulfiram 1073	Red: Avoid combination	Do not coadminister: potential toxicity	Disulfiram reaction (eg, headache, hypotension, flushing, vomiting)	Not studied		Oral solution contains alcohol	Do not coadminister with ritonavir solution
Ritonavir Triazolam 1072	Red: Avoid combination	Do not coadminister: Increased levels of triazolam	Increased triazolam effects (eg, increased confusion, sedation, respiratory depression)		0.125 mg x 1 dose	Triazolam AUC increased 1939%; half-life: increased 1267%; Cmax increased 87%	Use alternative agents
Ritonavir Fluticasone 1071	Red: Avoid combination	Do not coadminister: Increased levels of fluticasone	Increased fluticasone effects (eg, Cushing's syndrome, adrenal suppression)		200 mcg once daily x 7 d	Fluticasone Cmax increased 2572%; AUC increased 36697%	Avoid combination and use alternative agents
Ritonavir Fluticasone 1070	Red: Avoid combination	Do not coadminister: Increased levels of fluticasone	Decreased plasma cortisol concentrations (eg, Cushing's syndrome, adrenal suppression)			Fluticasone AUC increased 350-fold; Cmax increased 25-fold	Avoid combination and use alternative agents
Ritonavir Escitalopram 1069	Green: Administer standard doses	Administer standard doses		No significant change	20 mg x 1 dose	No significant change
Ritonavir Cetirizine 1068	Green: Administer standard doses	Administer standard doses		Not studied	10 mg daily	Cetirizine AUC increased 42%; half-life: increased 52%; clearance: decreased 29%; Cmax no significant change
Ritonavir Mefloquine 1067	Green: Administer standard doses	Administer standard doses		AUC decreased 31%; Cmax increased 36%; Cmin decreased 43%	250 mg daily x 3 days, then once weekly for 3 weeks	No significant change
Ritonavir Fluconazole 1066	Green: Administer standard doses	Administer standard doses		Cmax increased 14.5%; AUC increased 12%; Cmin increased 14%	400 mg x 1 day, then 200 mg days 2-5
Ritonavir RAL 1065	Green: Administer standard doses	Administer standard doses			400 mg x 1	Raltegravir AUC decreased 16%; Cmax decreased 24%
Ritonavir TMP/SMX 1064	Green: Administer standard doses	Administer standard doses			160 mg / 800 mg x 1 dose	Sulfamethoxazole AUC decreased 20%; trimethoprim AUC increased 20%
Ritonavir Posaconazole 1063	Green: Administer standard doses	Administer standard doses	Potential increased ritonavir effects	Ritonavir AUC increased 80%; Cmax increased 49%	400 mg BID
Ritonavir Fluoxetine 1062	Green: Administer standard doses	Administer standard doses	Increased ritonavir effects; Potential increased fluoxetine effects	AUC increased 19%; Cmax no significant change	30 mg Q12H
Ritonavir Beclomethasone 1061	Green: Administer standard doses	Administer standard doses		Not studied	160 mcg inhaled BID	Beclomethasone-17-monopriopionate AUC increased 108%; Cmax increased 67%	Use lowest possible dose and titrate to effect
Ritonavir EFV 1060	Green: Administer standard doses	Administer standard doses	Possible increased effects of both drugs	Ritonavir AUC increased 18%	600 mg daily	Efavirenz AUC increased 21%	No dose adjustment required for boosting doses of ritonavir
Ritonavir Dabigatran 1059	Green: Administer standard doses	Administer standard doses	Potential for increased risk of bleeding	Not studied		Not studied (may increase dabigatran levels)	No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Ritonavir Zolpidem 1058	Green: Administer standard doses	Administer standard doses	Increased zolpidem effects (eg, increased sedation, confusion)		5 mg x 1 dose	Zolpidem AUC increased 28%; Cmax increased 22%	Monitor for excess sedation
Ritonavir Levothyroxine 1057	Green: Administer standard doses	Administer standard doses	Increased TSH levels (eg, Signs and symptoms of hypothyroidism)		0.125 mg		Monitor and increase levothyroxine dose as indicated
Ritonavir Desipramine 1056	Green: Administer standard doses	Administer standard doses	Increased desipramine effects (eg, dry mouth, dizziness, urinary retention)	Not studied		Desipramine clearance: decreased 59%	Monitor and adjust desipramine as indicated
Ritonavir Amitriptyline 1055	Green: Administer standard doses	Administer standard doses	Increased amitriptyline effects (eg, dry mouth, hypotension, confusion)	Not studied		Not studied (may increase amitriptyline levels)	Monitor and adjust amitriptyline as indicated
Ritonavir Prednisolone 1054	Green: Administer standard doses	Administer standard doses	Potential increased prednisolone effects (adrenal insufficiency, Cushing's syndrome).		20 mg x 1 dose	Prednisolone AUC increased 30%; clearance: decreased 23%	Do not coadminister unless potential benefits of prednisone outweigh the risks of systemic corticosteroid adverse effects.
Ritonavir Methadone 1053	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone			Stable methadone dose	No significant effect	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Ritonavir Methadone 1052	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Not clinically significant			S-methadone AUC decreased 25%; R-methadone AUC decreased 20%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Ritonavir Methadone 1051	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, methadone withdrawal)		90 mg daily x 2 years	Methadone AUC decreased	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Ritonavir Warfarin 1050	Yellow: Adjust dosing	Adjust dosing to avoid increased or reduced levels of warfarin	Decreased warfarin effects (eg, decreased INR, increased risk of clotting)		12.5 mg daily	INR: decreased	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Ritonavir Vardenafil 1049	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of vardenafil	Increased tadalafil effects		5 mg daily	Vardenafil AUC increased 49-fold; Cmax increased 13-fold. T1 / 2 increased to 26 hours.	Initiate (and do not exceed) vardenafil 2.5 mg every 72 hours and monitor for adverse effects
Ritonavir Trazodone 1048	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of trazodone	Increased trazodone effects (eg, nausea, hypotension, syncope)	Not studied	50 mg x 1 dose	Trazodone AUC increased 240%; Cmax increased 34%; half-life: increased 220%	Decrease trazodone dose or start low and titrate to effect
Ritonavir Trazodone 1047	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of trazodone	Increased trazodone effects (eg, nausea, dizziness, hypotension, syncope)			Trazodone AUC increased 2.4-fold; Cmax increased 34%	Decrease trazodone dose or start low and titrate to effect
Ritonavir Tadalafil 1046	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of tadalafil	Increased tadalafil effects (eg, hypotension, priapism)		20 mg x 1	Tadalafil AUC increased 32%, Cmax decreased 30%	For erectile dysfunction initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
Ritonavir Tadalafil 1045	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of tadalafil	Increased tadalafil effects (eg, hypotension, priapism)		20 mg x 1	Tadalafil AUC increased 124%	For erectile dysfunction initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
Ritonavir Sildenafil 1044	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	Increased sildenafil effects (eg, hypotension, priapism)		100 mg x 1 dose	Sildenafil AUC increased 1000%; Cmax increased 290%; Tmax: delayed 3 hours	For erectile dysfunction, initiate sildenafil 25 mg every 48 hours and monitor for adverse effects. Manufacturer recommends not to exceed dose of 25 mg every 48 hours. Do not coadminister if using sildenafil for pulmonary arterial hypertension.
Ritonavir RFB 1043	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Increased rifabutin effects (eg, uveitis)		150 mg daily x 24 days	Rifabutin AUC increased 400%; Cmax increased 250%	Decrease rifabutin to 150 mg every other day or 300 mg 3 times / week
Ritonavir MVC 1042	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Increased maraviroc effects		100 mg BID	Maraviroc AUC increased 161%; Cmin increased 355%; Cmax increased 28%	Reduce dose of maraviroc to 150 mg BID with strong CYP3A4 inhibitors
Ritonavir Fentanyl 1041	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of fentanyl	Increased fentanyl effects (eg, increased sedation, confusion, respiratory depression)		5 mcg / kg	Fentanyl clearance decreased 67%	Monitor closely, start with low dose and titrate to pain response as indicated
Ritonavir Digoxin 1040	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of digoxin	Increased digoxin effects		0.4 mg x 1 dose	Digoxin AUC (0-8 hr): increased 29%; AUC (0-72 hr): increased 22%; clearance: decreased 30%; half-life: increased 43%	Digoxin dose may need to be decreased. Monitor digoxin level and adjust digoxin dose based on clinical signs and drug levels.
Ritonavir Colchicine 1039	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	Increased colchicine effects		0.6 mg x 1	Colchicine AUC increased 296%; Cmax increased 184%	For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
Ritonavir Clarithromycin 1038	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	Increased clarithromycin effects	AUC no significant change; Cmax increased 15%	500 mg BID	Clarithromycin AUC increased 77%; Cmax increased 31%; Cmin increased 182%	Reduce clarithromycin dose by 50% in patients with CrCl 30-60 mL / min. Reduce clarithromycin dose by 75% in patients with CrCl <30 mL / min.
Ritonavir Bosentan 1037	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of bosentan	Possible increased bosentan effects	Not studied		Not studied (may increase bosentan levels)	Start low and titrate bosentan to effect. If patient has been on protease inhibitor (other than unboosted atazanavir) for more than 10 days, start bosentan at 62.5 mg daily or every other day. If patient is currently on bosentan and requires a PI (other than unboosted atazanavir), stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day.
Ritonavir ATV 1036	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Increased atazanavir effects	Not studied	300 mg daily on days 1-20	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
Ritonavir Olanzapine 1035	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of olanzapine	Decreased olanzapine effects	Not studied	10 mg daily	Olanzapine AUC decreased 53%; half-life: decreased 50%; clearance: increased 115%; Cmax decreased 40%	Monitor clinical improvement and adjust olanzapine as indicated
Ritonavir ETR 1034	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of etravirine				Etravirine AUC decreased 46%; Cmax decreased 32%	For ritonavir boosting - refer to individual protease inhibitors for specific recommendation
Atazanavir RTV 821	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Not studied; Potential increased atazanavir levels)			Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
Atazanavir RTV 755	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Increased atazanavir effects	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	100 mg daily on days 11-20	Not studied	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
Nevirapine RTV 593	Green: Administer standard doses	Administer standard doses		Nevirapine AUC decreased 40%	600 mg BID	No significant change	No dose adjustment necessary
Etravirine RTV 513	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of etravirine	Significant decrease in etravirine concentration and loss of theraputic effect		600 mg BID
Efavirenz RTV 410	Green: Administer standard doses	Administer standard doses	Increased efavirenz and ritonavir effects	Efavirenz AUC increased 21%; Cmax no significant change	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose
Efavirenz RTV 409	Green: Administer standard doses	Administer standard doses	Increased efavirenz and ritonavir effects	Efavirenz AUC increased 21%; Cmax no significant change	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose
Doravirine RTV 345	Green: Administer standard doses	Administer standard doses	Potential for increased doravirine adverse effects	AUC increased to 354%; Cmax increased by 31%; C24 increased to 291%	100 mg BID	Not studied	No dose adjustment necessary. Monitor for doravirine adverse effects.
Raltegravir RTV 308	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 16%; Cmax decreased 24%	100 mg BID	Not reported
Dolutegravir ETR + DRV/r 106	Green: Administer standard doses	Administer standard doses		Cmax decreased 12%, AUC decreased 25%, Cmin decreased 37%	200 mg + 600 / 100 mg BID	Not studied
Maraviroc RTV 47	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 161%; Cmax increased 28%	100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Fostemsavir RTV 9	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 53%, AUC increased 45%, Cmin increased 44%	100 mg once daily	Not reported
Ritonavir

Subscribe to Ritonavir